Who are the top shareholders of the Metropolis Healt?

The top shareholders of Metropolis Health include Metz Advisory LLP with 30.29%, mutual funds holding 26.42% (led by HDFC Mutual Fund at 9.64%), foreign institutional investors at 15.29%, and individual investors at 3.84%.

The top shareholders of Metropolis Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with Metz Advisory LLP holding the highest stake at 30.29%. Mutual funds collectively hold 26.42% of the company, with HDFC Mutual Fund - HDFC Focused 30 Fund being the largest public shareholder at 9.64%. Additionally, FIIs own 15.29% of the shares, while individual investors hold 3.84%.

how big is Metropolis Healt?

As of Jun 06, Metropolis Healthcare Ltd has a market capitalization of 8,629.00 Cr, with recent net sales of 1,331.21 Cr and a net profit of 144.97 Cr for the latest four quarters. Shareholder's funds are valued at 1,096.16 Cr, and total assets amount to 1,547.43 Cr as of Mar'24.

Market Cap: As of Jun 06, Metropolis Healthcare Ltd has a market capitalization of 8,629.00 Cr, which classifies it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported a sum of Net Sales of 1,331.21 Cr and a sum of Net Profit of 144.97 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 1,096.16 Cr, and the Total Assets amount to 1,547.43 Cr.

Has Metropolis Healt declared dividend?

Metropolis Healthcare Ltd has declared a 200% dividend, amounting to ₹4 per share, with an ex-date of November 17, 2023. Despite this declaration, the dividend yield is 0%, and recent total returns have been mixed, showing negative performance in the short term and more favorable results over longer periods.

Metropolis Healthcare Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 4<BR>- Ex-date: 17 Nov 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.5%, with no dividend return, resulting in a total return of -22.5%.<BR><BR>Over the past year, the price return was -18.18%, with no dividend return, leading to a total return of -18.18%.<BR><BR>In the 2-year period, the price return was 26.39%, with a dividend return of 0.29%, resulting in a total return of 26.68%.<BR><BR>For the 3-year period, the price return was 3.34%, with a dividend return of 0.86%, culminating in a total return of 4.2%.<BR><BR>In the last 4 years, the price return was -34.24%, with a dividend return of 0.71%, leading to a total return of -33.53%.<BR><BR>Over the past 5 years, the price return was 14.39%, with a dividend return of 2.07%, resulting in a total return of 16.46%.<BR><BR>Overall, while Metropolis Healthcare Ltd has declared a significant dividend, the total returns over the recent periods show a mixed performance, with negative returns in the shorter terms and more favorable returns over longer periods. The dividend yield remains at 0%, indicating that the declared dividend has not yet positively impacted the yield for investors.

Who are the peers of the Metropolis Healt?

Metropolis Healt's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Thyrocare Tech., Suven Life Scie., Vimta Labs, Laxmi Dental, and Krsnaa Diagnost. Metropolis Healt has a 1-year return of -11.47%, lower than Syngene Intl.'s -3.47%, with varying management and growth risks among its peers.

Peers: The peers of Metropolis Healt are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Thyrocare Tech., Suven Life Scie., Vimta Labs, Laxmi Dental, and Krsnaa Diagnost.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest. Below Average management risk is present at Suven Life Scie. and Krsnaa Diagnost. Growth is Excellent at Laxmi Dental, Good at Vimta Labs, and Average at Poly Medicure, Indegene, and the rest. Below Average growth is noted at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 161.32%, while the lowest is Syngene Intl. at -3.47%. Metropolis Healt's 1-year return is -11.47%, which is lower than Syngene Intl. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., and Krsnaa Diagnost.

Who are in the management team of Metropolis Healt?

As of March 2023, the management team of Metropolis Health includes Sushil Kanubhai Shah (Chairman & Executive Director), Ameera Sushil Shah (Managing Director), and several independent directors, along with a non-executive director and a company secretary, ensuring a diverse governance structure.

As of March 2023, the management team of Metropolis Healt includes the following individuals:<BR><BR>1. Sushil Kanubhai Shah - Chairman & Executive Director<BR>2. Ameera Sushil Shah - Managing Director<BR>3. Vivek Gambhir - Independent Director<BR>4. Sanjay Bhatnagar - Independent Director<BR>5. Milind Shripad Sarwate - Independent Director<BR>6. Anita Ramachandran - Independent Director<BR>7. Hemant Sachdev - Non-Executive & Non-Independent Director<BR>8. Neha Shah - Company Secretary & Compliance Officer<BR><BR>This team comprises a mix of executive, independent, and non-executive members, reflecting a diverse governance structure.

What does Metropolis Healt do?

Metropolis Healthcare Ltd is a mid-cap company in the healthcare services industry, reporting net sales of ₹3,453 Cr and a net profit of ₹291 Cr for Q1 2025. Key metrics include a P/E ratio of 71.00 and a market cap of ₹10,130 Cr.

Overview:<BR>Metropolis Healthcare Ltd operates in the healthcare services industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was established in January 1980 as a partnership firm and has undergone several changes in partnership structure. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,453 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 291 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 10,130 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 71.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.06 <BR>Return on Equity: 10.89% <BR>Price to Book: 7.28 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

When is the next results date for Metropolis Healt?

Metropolis Health will announce its results on August 7, 2025.

Metropolis Healt will declare its results on 07 August 2025.

Are Metropolis Healt latest results good or bad?

Metropolis Healthcare's latest results show strong sales and profit growth, with net sales up 11.81% and PAT rising 24.3%. However, concerns about increased borrowing costs and decreased liquidity suggest the company faces challenges despite its positive performance.

Metropolis Healthcare's latest results present a mixed picture. On one hand, the company has shown significant improvements in key financial metrics. Net sales reached Rs 386.06 crore, marking an 11.81% increase compared to the previous quarter, which is the highest in the last five quarters. Additionally, the Profit Before Tax (PBT) grew by 22.2%, and Profit After Tax (PAT) rose by 24.3%, indicating strong profitability growth.<BR><BR>Moreover, the company's debt-equity ratio has improved to 0.15 times, the lowest in the last five half-year periods, suggesting a healthier balance sheet with reduced reliance on debt. However, there are some challenges to consider. The company recorded its highest quarterly interest expense at Rs 5.20 crore, indicating increased borrowing costs. Furthermore, cash and cash equivalents have decreased to Rs 49.02 crore, the lowest in six half-yearly periods, which raises concerns about short-term liquidity. The decrease in the debtors turnover ratio to 9.00 times also suggests a slowdown in settling debts.<BR><BR>In summary, while Metropolis Healthcare has achieved strong sales and profit growth, the challenges related to liquidity and increased borrowing costs could be areas of concern. Overall, the results can be seen as a positive step forward, but the company will need to address these challenges to maintain its momentum.

Is Metropolis Healt overvalued or undervalued?

As of September 8, 2025, Metropolis Health is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 73.15, an EV to EBITDA ratio of 35.71, and a PEG ratio of 7.47, despite outperforming the Sensex over three years.

As of 8 September 2025, the valuation grade for Metropolis Health has moved from very expensive to expensive, indicating a slight easing in perceived overvaluation. The company is currently considered overvalued based on its high valuation metrics, including a PE ratio of 73.15, an EV to EBITDA ratio of 35.71, and a PEG ratio of 7.47. <BR><BR>In comparison to its peers, Metropolis Health's PE ratio is notably higher than Apollo Hospitals at 71.12 and Narayana Hrudaya at 46.06, both of which are also categorized as expensive. The company's recent stock performance has shown a 1-week decline of 0.79%, contrasting with a 0.53% gain in the Sensex, although it has outperformed the index over a 3-year period with a return of 45.26% compared to the Sensex's 35.35%. Overall, Metropolis Health appears to be overvalued in the current market environment.

How has been the historical performance of Metropolis Healt?

Metropolis Healt has shown consistent growth in net sales and profitability, with net sales increasing from 761.18 Cr in March 2019 to 1,331.20 Cr in March 2025, and profit after tax reaching 145.51 Cr in the same period. The company's total assets and liabilities have also significantly grown, reflecting a robust financial performance.

Answer:<BR>The historical performance of Metropolis Healt shows a consistent growth in net sales and profitability over the years, with a notable increase in the most recent fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Metropolis Healt's net sales have risen from 761.18 Cr in March 2019 to 1,331.20 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, reaching 1,331.20 Cr in March 2025, up from 761.18 Cr in March 2019. The company's total expenditure has also increased, amounting to 1,028.21 Cr in March 2025, compared to 560.81 Cr in March 2019. Operating profit, excluding other income, has shown fluctuations but reached 302.99 Cr in March 2025, while profit before tax was recorded at 190.85 Cr. The profit after tax for March 2025 was 145.51 Cr, indicating a steady profitability despite some variations in previous years. The company's total assets have grown significantly from 738.33 Cr in March 2020 to 1,859.09 Cr in March 2025, while total liabilities increased from 738.33 Cr to 1,859.09 Cr in the same period. Cash flow from operating activities has remained relatively stable, with 262.00 Cr in March 2025, although the net cash outflow was recorded at -23.00 Cr. Overall, Metropolis Healt has demonstrated a robust growth pattern in revenue and profitability, alongside an increase in assets and liabilities over the years.

Should I buy, sell or hold Metropolis Healt?

Is Metropolis Healt technically bullish or bearish?

As of November 24, 2025, Metropolis Health shows a mildly bullish trend driven by daily moving averages, but caution is advised due to bearish signals from the weekly MACD and KST.

As of 24 November 2025, the technical trend for Metropolis Healt has changed from sideways to mildly bullish. The current stance is mildly bullish, primarily driven by the daily moving averages indicating a bullish sentiment. However, the weekly MACD and KST are both mildly bearish, suggesting some caution in the short term. The monthly MACD remains bullish, providing a stronger long-term outlook. Bollinger Bands show a mixed signal with a bearish stance on the weekly and a mildly bullish stance on the monthly. Overall, while there are bullish indicators, the presence of bearish signals in the weekly timeframe indicates a cautious approach is warranted.

Which are the latest news on Metropolis Healt?

Why is Metropolis Healt falling/rising?

As of 03-Dec, Metropolis Healthcare Ltd's stock price is rising to 1,971.10, driven by strong relative performance, increased investor participation, and positive financial results, indicating a favorable short-term outlook despite year-to-date challenges.

As of 03-Dec, Metropolis Healthcare Ltd's stock price is rising, currently at 1,971.10, reflecting an increase of 27.05 or 1.39%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.29% today, indicating strong relative performance. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 17.53% compared to the 5-day average, suggesting growing interest among investors.<BR><BR>Moreover, the company demonstrates high management efficiency, evidenced by a return on equity (ROE) of 16.21% and a low debt-to-equity ratio of 0.08 times, which are positive indicators for potential investors. The positive financial results reported for September, including the highest operating cash flow at Rs 275.01 crore and net sales of Rs 429.19 crore, further bolster investor confidence.<BR><BR>While the stock has faced challenges over longer periods, such as a decline of 4.47% year-to-date, the current performance metrics and rising investor participation suggest a favorable outlook in the short term, contributing to the stock's recent rise.